Pact Pharma develops personalized adoptive T cell therapies that target and eliminate solid tumors by harnessing the body's immune system. Their approach addresses the limitations of conventional cancer treatments by providing tailored therapies that enhance patient-specific immune responses against tumor cells.
Funding
$75M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Solid tumors pose a significant challenge in cancer treatment due to their complex and heterogeneous nature, often evading conventional therapies. Traditional approaches may not effectively target the unique characteristics of each patient's tumor, leading to limited efficacy and potential for recurrence.
Solution
Pact Pharma is developing personalized adoptive T cell therapies designed to target and eliminate solid tumors by leveraging the patient's own immune system. This approach aims to overcome the limitations of conventional cancer treatments by creating tailored therapies that enhance patient-specific immune responses against their individual tumor cells. By identifying and engineering T cells to recognize and attack tumor-specific antigens, Pact Pharma seeks to provide more effective and durable responses in patients with solid tumors. The personalized nature of these therapies allows for a more precise and targeted approach, potentially minimizing off-target effects and maximizing therapeutic benefit.
Target Audience
Pact Pharma's therapies are intended for patients with solid tumors who may benefit from a personalized approach that harnesses their own immune system to fight cancer.
Features
- Personalized adoptive T cell therapies tailored to each patient's unique tumor antigens.
- Identification and engineering of T cells to specifically target tumor cells.
- Enhancement of patient-specific immune responses against solid tumors.
- Potential for more effective and durable responses compared to conventional treatments.